Contents
pdf Download PDF
pdf Download XML
79 Views
31 Downloads
Share this article
Research Article | Volume 18 Issue 11 (November, 2026) | Pages 461 - 467
Comparison of Right Ventricular Dysfunction Between Patients with Acute Exacerbation and Stable Chronic Obstructive Pulmonary Disease Using Echocardiography
 ,
 ,
 ,
 ,
 ,
1
Senior Registrar Cardiology, Punjab Institute of Cardiology Lahore, Pakistan
2
Specialty Registrar Cardiology, Punjab Institute of Cardiology Lahore, Pakistan
3
Pediatric Interventional Cardiologist, Peshawar General Hospital Peshawar Pakistan
4
Associate Professor Pulmonology and Allergy, Rehman Medical Institute, Peshawar Pakistan
5
Medical Officer Cardiology, Khyber Teaching Hospital, Peshawar Pakistan
6
Medical Officer (MD Radiology), Radiology Department, Sadiq Abbasi Hospital, Bahawalpur
Under a Creative Commons license
Open Access
Received
Aug. 14, 2026
Revised
Oct. 27, 2026
Accepted
Nov. 8, 2026
Published
Nov. 20, 2026
Abstract

Chronic obstructive pulmonary disease (COPD) is associated with pulmonary vascular changes and right ventricular (RV) dysfunction. Acute exacerbation can further impair the function of the RV. Objective: To compare RV dysfunction between patients with acute exacerbation and stable COPD using echocardiography. Methods: A comparative cross-sectional study was conducted at Pakistan Institute of Cardiology, Lahore, over six months. A total of 258 patients were included, with 129 patients in each group. Transthoracic echocardiography was used to evaluate TAPSE, RVFAC, tissue Doppler-derived S′, pulmonary artery systolic pressure, and RV dimensions. RV dysfunction was defined as TAPSE below 17 mm and/or RVFAC below 35%. Results: Echocardiography showed significantly lower TAPSE, RVFAC, and S′, along with greater right ventricular dimensions and pulmonary artery systolic pressure in the acute exacerbation group. Right ventricular dysfunction was observed in 42.6% of patients with acute exacerbation compared with 23.3% of stable COPD patients (p=0.001). Acute exacerbation remained independently associated with right ventricular dysfunction after adjustment for potential confounders (p=0.008). Conclusion: Right ventricular dysfunction was significantly more frequent among patients with acute exacerbation of COPD than those with stable disease. Patients with acute exacerbation also had lower right ventricular systolic function as indicated by lower TAPSE, lower RVFAC, and lower tissue Doppler-derived S′ and higher pulmonary artery systolic pressure and right ventricular dimensions.

Keywords
INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a chronic progressive lung disease with a progressive loss of airflow, long-term airway inflammation, and structural changes in the lungs.[1] It is a significant global public health issue due to its high morbidity, mortality, and health care costs.[2] The World Health Organization considered COPD the third leading cause of death in the world in 2023, causing some 3.5 million deaths, or about 5.8% of all deaths globally.[3] The Global Burden of Disease Study found that around 213.4 million people had COPD in 2021, which has a significant impact on population health.[4]

 

Cardiovascular complications are significant extrapulmonary complications of COPD, and right ventricular (RV) dysfunction appears to be a particular complication of COPD, as it is associated with pulmonary vascular changes and right ventricular afterload.[5]

 

Increased pulmonary arterial pressure leads to pulmonary remodeling, destruction of pulmonary capillary beds, hypoxic pulmonary vasoconstriction, and chronic hypoxemia, which results in RV remodeling.[6] Initially, these changes may be seen as right ventricular hypertrophy and dilatation, which can later lead to the development of impaired systolic function and right-sided heart failure.[7] In addition, a cardiac component can be asymptomatic and not be part of the clinical picture, which is often dominated by respiratory symptoms, making the assessment of cardiac function a crucial component in the evaluation of a patient with COPD.[8]

 

Acute exacerbations of COPD are an acute worsening of respiratory symptoms, frequently associated with increased airway inflammation, hypoxemia, hypercapnia, and changes in pulmonary hemodynamics.[9] These changes can acutely affect pulmonary vascular resistance and right heart workload, which could exacerbate underlying cardiac dysfunction.[9] A 2022 cross-sectional study, comparing patients with recent acute exacerbation and clinically stable COPD, found differences in cardiac structure and function between the two clinical groups, suggesting that exacerbations could have a significant impact on the cardiovascular system.[10] More recently, a multicenter prospective study of 250 patients in 2025 showed that the tricuspid regurgitation gradient was significantly greater during acute exacerbation than during the stable phase (35.7±16.0 mmHg and 29.7±16.6 mmHg, respectively; p=0.001), suggesting increased right-sided cardiac pressure during acute illness.[11]

 

Transthoracic echocardiography is a non-invasive and clinically accessible tool to assess the structure, function, and pulmonary hemodynamics of the right ventricle in COPD patients.[12] Tricuspid annular plane systolic excursion (TAPSE), right ventricular fractional area change (RVFAC), tissue Doppler-derived tricuspid annular systolic velocity (S′), right ventricular dimensions, and estimated pulmonary artery systolic pressure (PASP) are important echocardiographic parameters.[13] These measurements aid in the diagnosis of right ventricular systolic dysfunction, ventricular dilatation, and pulmonary hypertension. Echocardiographic evaluation can be especially helpful in acute exacerbations when shifts in oxygenation, pulmonary vascular resistance, and/or right ventricular performance may affect the RV.[14]

 

Although there is a well-recognized association between the COPD and cardiovascular dysfunction, there is an important clinical question whether RV dysfunction is different between the patients with acute exacerbation or clinically stable COPD. Furthermore, significant differences in echocardiographic parameters between these groups may be useful to distinguish the contribution of the cardiovascular system to acute respiratory deterioration. It would assess relevant echo parameters such as TAPSE, pulmonary artery systolic pressure, right ventricular dimensions, and RVFAC to assess differences in right ventricular function between the two groups. The findings may provide clinically relevant evidence regarding the importance of echocardiographic assessment in the cardiovascular evaluation of patients with COPD. Therefore, the present study aimed to compare the frequency of right ventricular dysfunction between patients with acute exacerbation and stable COPD using echocardiography.

MATERIALS AND METHODS

A comparative cross-sectional study was conducted at the Pakistan Institute of Cardiology (PIC), Lahore, Pakistan. This study took place for six months from 1st November 2025 to 30th April 2026.

 

The sample size was estimated using the findings of a previous multicentre prospective study by Rastoder et al. (2025), which reported a mean tricuspid regurgitation (TR) gradient of 35.7 ± 16.0 mmHg during acute COPD exacerbation and 29.7±16.6 mmHg during the stable phase, representing a mean difference of 6.0 mmHg.[11] Using a two-sided confidence level of 95%, statistical power of 80%, an equal allocation ratio, and a pooled standard deviation of approximately 16.3 mmHg, the calculated sample size was 116 patients in each group. After adding 10% to account for incomplete data or technically inadequate echocardiographic examinations, the final sample size was 258 patients (129 in each group).

 

The eligible patients were recruited by non-probability consecutive sampling. Eligible patients were screened in the cardiology OPD, ED, and Inpatient services at PIC Lahore. The patients who qualified were enrolled consecutively until the desired number of patients was obtained. Patients were allocated to either of the two groups, acute exacerbation group or stable COPD group, based on clinical presentation at the time of recruitment.

 

Patients were included if they were 40 years or older, had a confirmed diagnosis of COPD based on post-bronchodilator spirometry with an FEV₁/FVC ratio of less than 0.70, and were of either gender. The acute exacerbation group included patients with acute exacerbation of respiratory symptoms (dyspnea, cough, or increase in sputum production) who needed further treatment. The stable group of COPD was defined as a patient who did not have any exacerbation, hospital admission, or need for extra treatment for COPD symptoms over the previous 3 months.

 

Patients who had previously been diagnosed with PAH, CHD, and severe valvular heart disease, ischemic heart disease with recent ACS, cardiomyopathy, or LVEF <50% were excluded. Other exclusion criteria included patients with chronic kidney disease, prior known pulmonary embolism, interstitial lung disease, bronchiectasis, and other major lung diseases. Patients with atrial fibrillation or other severe cardiac arrhythmias, patients with poor echocardiographic images, and patients with a history of cardiac surgery were not included in the study.

 

After obtaining approval from the institutional ethical review committee of the hospital, eligible patients were approached, and written informed consent was obtained before enrolment. A structured data collection proforma was used to gather demographic and clinical data. All the variables recorded were age, gender, BMI, smoking history, COPD duration, comorbidities, previous exacerbations, and medication history. Clinical assessments were made, including HR, BP, RR, oxygen saturation, and oxygen requirement. Patients' clinical presentation was categorized into acute exacerbation and stable COPD groups, and the diagnosis of COPD was confirmed by reviewing the patients' spirometry reports.

The transthoracic echocardiograms were carried out using a conventional echocardiographic machine by an experienced cardiologist in all participants. The examination was carried out in the usual manner, in the left lateral decubitus position. Right ventricular dimensions were evaluated on the apical four-chamber view, and right ventricular systolic function was evaluated by tricuspid annular plane systolic excursion (TAPSE), right ventricular fractional area change (RVFAC), and tissue Doppler-derived tricuspid annular systolic velocity (S′). M-mode was used to measure TAPSE, and right ventricular end-diastolic and end-systolic areas were used to calculate RVFAC. Pulmonary artery systolic pressure (PASP) was estimated from the peak tricuspid regurgitation velocity using the modified Bernoulli equation, with estimated right atrial pressure added to the calculated pressure gradient.

 

Right ventricular systolic dysfunction was defined as TAPSE below 17 mm and/or RVFAC below 35%. A TAPSE < 17 mm suggested diminished longitudinal right RV systolic function, while RVFAC < 35% suggested poor global RV systolic function. Right ventricular dysfunction presence or absence was noted as the primary outcome, and individual echocardiographic measurements were recorded as secondary outcomes. All echocardiographic measurements were made using a set of predetermined criteria to ensure consistency between the two groups.

IBM SPSS Statistics, version 26.0, was used for data entry and analysis. The Shapiro-Wilk test was used to determine normality of quantitative variables such as age, BMI, duration of COPD, oxygen saturation, TAPSE, RVFAC, S′, right ventricle dimensions, and PASP. Normally distributed variables are presented as mean ± SD, and non-normally distributed variables are presented as median (IQR). The categorical variables, including gender, smoking status, co-morbid conditions, and right ventricular dysfunction, were summarized as frequencies and percentages.

 

The independent-samples t-test was used to compare normally distributed continuous variables between the two groups, while the Mann-Whitney U test was applied to non-normally distributed variables. The chi-square test was used to compare categorical variables. The incidence of RV dysfunction was compared between the two groups: those with acute exacerbation and those with stable COPD. A binary logistic regression analysis was used to determine whether right ventricular dysfunction was associated with acute exacerbation following adjustment for potential confounders such as age, gender, smoking history, COPD duration, and severity. Results were reported as odds ratios with 95% confidence intervals. Statistically significant p-values were set at ≤0.05.

 

RESULTS

A total of 258 patients with COPD were included in the study, comprising 129 patients with acute exacerbation and 129 patients with stable COPD. The mean age was comparable between the two groups (64.8 ± 9.2 vs. 62.9 ± 8.7 years; p=0.091). The gender ratio, BMI, smoking, duration of COPD, hypertension, and diabetes mellitus were not significantly different. Patients with acute exacerbation, however, had significantly more exacerbations than did patients with stable COPD (p=0.003). (Table 1)

 

Patients with acute exacerbation had significantly higher heart rate and respiratory rate, along with lower oxygen saturation, compared with patients with stable COPD (all p<0.001). The acute exacerbation group also had a higher oxygen requirement (78.3% vs 24.0%; p<0.001). Moreover, the FEV₁ and FEV₁/FVC ratio were found to be significantly decreased in patients with AEA. There was also a significant difference in the distribution of GOLD spirometric grades between the groups (p=0.003). (Table 2)

 

Higher values of echocardiographic assessment were shown to be significantly abnormal in patients with acute exacerbation. Mean TAPSE, RVFAC, and tissue Doppler-derived S′ were lower in the acute exacerbation group than in the stable COPD group (all p<0.001). Conversely, right ventricular basal and mid-cavity dimensions, pulmonary artery systolic pressure, and tricuspid regurgitation gradient were significantly higher in patients with acute exacerbation (all p<0.001). (Table 3)

Right ventricular dysfunction, defined as TAPSE below 17 mm and/or RVFAC below 35%, was identified in 55 (42.6%) patients with acute exacerbation compared with 30 (23.3%) patients with stable COPD. This difference was statistically significant (p=0.001). There was also a higher prevalence of reduced TAPSE and RVFAC in the acute exacerbation group (p=0.002 and p=0.012, respectively). (Table 4)

 

This association between acute exacerbation and RV dysfunction persisted after adjusting for potential confounding factors in multivariable logistic regression (adjusted OR=2.18 (95% CI 1.22-3.89); p=0.008). Older age was also associated with increased odds of right ventricular dysfunction (adjusted OR: 1.03, 95% CI: 1.00-1.06; p=0.041), while higher FEV₁ percentage predicted was associated with decreased odds (adjusted OR: 0.97, 95% CI: 0.95-0.99; p=0.006). Gender, smoking, duration of COPD, hypertension, and diabetes mellitus were not independent risk factors for right ventricular dysfunction. (Table 5)

 

Table 1. Comparison of demographic and baseline characteristics between patients with acute exacerbation and stable COPD (n=258)

Variables

Acute exacerbation (n=129)

 n (%)/Mean ± SD

Stable COPD (n=129)

n (%)/Mean ± SD

p-value

Age (years),

64.8 ± 9.2

62.9 ± 8.7

0.091

Gender

 

 

 

Male

91 (70.5)

87 (67.4)

0.594

Female

38 (29.5)

42 (32.6)

—

BMI (kg/m²)

22.6 ± 4.1

23.4 ± 4.3

0.128

Current smokers

72 (55.8)

68 (52.7)

0.619

Former smokers

42 (32.6)

45 (34.9)

—

Never smokers,

15 (11.6)

16 (12.4)

—

Duration of COPD (years)

8.2 ± 4.6

7.6 ± 4.2

0.269

Previous exacerbations, median (IQR)

2 (1-3)

1 (0-2)

0.003

Hypertension

56 (43.4)

52 (40.3)

0.614

Diabetes mellitus

35 (27.1)

32 (24.8)

0.664

 

 

Table 2. Comparison of clinical characteristics and pulmonary parameters between the two groups

Variables

Acute exacerbation (n=129)

n (%)/Mean ± SD

Stable COPD (n=129)

n (%)/Mean ± SD

p-value

Heart rate (beats/min)

104.6 ± 15.2

86.3 ± 12.4

<0.001

Systolic BP (mmHg)

126.4 ± 17.8

128.7 ± 16.5

0.276

Diastolic BP (mmHg)

78.2 ± 10.6

80.1 ± 9.8

0.128

Respiratory rate (breaths/min)

26.8 ± 4.5

19.6 ± 3.2

<0.001

Oxygen saturation (%)

86.5 ± 5.8

93.2 ± 3.1

<0.001

Supplemental oxygen requirement

101 (78.3)

31 (24.0)

<0.001

FEV₁ (% predicted)

38.6 ± 12.4

43.2 ± 13.1

0.004

FEV₁/FVC ratio

0.48 ± 0.09

0.51 ± 0.08

0.006

GOLD

 

 

 

Grade 1

0 (0.0)

9 (7.0)

0.003

Grade 2

23 (17.8)

37 (28.7)

—

Grade 3

70 (54.3)

65 (50.4)

—

Grade 4

36 (27.9)

18 (14.0)

—

Inhaled triple therapy

79 (61.2)

84 (65.1)

0.513

 

 

Table 3. Comparison of echocardiographic parameters between patients with acute exacerbation and stable COPD

Echocardiographic parameters

Acute exacerbation (n=129)

Mean ± SD

Stable COPD (n=129)

Mean ± SD

p-value

TAPSE (mm)

17.1 ± 3.2

19.0 ± 3.1

<0.001

RVFAC (%)

34.2 ± 7.1

38.1 ± 6.8

<0.001

Tricuspid annular S′ (cm/s)

9.4 ± 1.8

10.6 ± 1.7

<0.001

RV basal diameter (mm)

43.2 ± 5.8

39.8 ± 5.2

<0.001

RV mid-cavity diameter (mm)

35.1 ± 4.9

32.7 ± 4.5

<0.001

PASP (mmHg)

42.5 ± 12.8

35.8 ± 10.6

<0.001

TR gradient (mmHg)

34.6 ± 11.5

28.8 ± 9.7

<0.001

TAPSE: tricuspid annular plane systolic excursion; RVFAC: right ventricular fractional area change; S′: tissue Doppler-derived tricuspid annular systolic velocity; RV: right ventricle; PASP: pulmonary artery systolic pressure; TR: tricuspid regurgitation.

 

Table 4. Comparison of frequency of right ventricular dysfunction between the two groups

Variables

Acute exacerbation (n=129)

n (%)

Stable COPD (n=129)

n (%)

p-value

TAPSE below 17 mm

48 (37.2)

25 (19.4)

0.002

RVFAC below 35%

34 (26.4)

18 (14.0)

0.012

Right ventricular dysfunction*

55 (42.6)

30 (23.3)

0.001

No right ventricular dysfunction

74 (57.4)

99 (76.7)

—

*Defined as TAPSE below 17 mm and/or RVFAC below 35%. Individual echocardiographic abnormalities were not mutually exclusive.

 

Table 5. Multivariable logistic regression analysis of factors associated with right ventricular dysfunction

Variables

Unadjusted OR

(95% CI)

p-value

Adjusted OR

(95% CI)

p-value

Acute exacerbation (vs stable COPD)

2.44 (1.43-4.16)

0.001

2.18 (1.22-3.89)

0.008

Age (per year increase)

1.04 (1.01-1.07)

0.012

1.03 (1.00-1.06)

0.041

Male gender

1.28 (0.75-2.19)

0.365

1.19 (0.66-2.15)

0.561

Current smoking

1.34 (0.80-2.24)

0.266

1.22 (0.69-2.16)

0.496

COPD duration (per year increase)

1.08 (1.02-1.14)

0.009

1.05 (0.99-1.12)

0.106

FEV₁ (% predicted, per 1% increase)

0.96 (0.94-0.98)

<0.001

0.97 (0.95-0.99)

0.006

Hypertension

1.42 (0.83-2.43)

0.198

1.26 (0.70-2.27)

0.440

Diabetes mellitus

1.31 (0.72-2.39)

0.379

1.18 (0.61-2.29)

0.621

DISCUSSION

In the present study, patients with acute exacerbation were compared to clinically stable chronic obstructive pulmonary disease (COPD) patients in terms of RV function. The main result was that patients with acute exacerbation were more likely to have RV dysfunction than patients with stable COPD (42.6% vs. 23.3%). Also, in patients with acute exacerbation, TAPSE, RVFAC, and tissue Doppler-derived S′ were significantly lower, with higher pulmonary artery systolic pressure (PASP) and RV dimensions. The results indicate more cardiac involvement on the right side during acute deterioration of the respiratory condition, but do not prove cause and effect.

 

In the present study, the frequency of RV dysfunction was higher than that reported by Mohammed et al. (2023), who assessed 100 moderate-to-very-severe COPD patients, finding that 25% had abnormal TAPSE, 17% had abnormal RV strain, and 9% had reduced FAC.[15] This increased frequency among the present study's acute exacerbation group may partly be due to the differences in clinical status, disease severity, and operational definition of RV dysfunction. Likewise, a 2025 study that included 100 COPD patients found that a higher percentage of patients had RV dilatation, RV wall thickening, and impaired longitudinal systolic function. These findings indicate the existence of structural and functional abnormalities of the RV in COPD. [16]

 

An important comparison can be made with Pereira et al. (2022), who assessed 40 patients, one-half with acute exacerbation of COPD and one-half with stable COPD. Their study, however, did not find any significant differences in cardiac structure or function between the two groups, unlike the present study findings. Their patients were evaluated about 30 days following exacerbation; however, the patients in this study were evaluated during exacerbation and during a stable clinical state. These variations in findings may be attributed to differences in assessment time, sample size, disease severity, and echocardiographic parameters. Their findings further indicate that cardiac alterations that occur during the acute disease do not always remain following clinical recovery.[17]

 

Our acute exacerbation group also had higher pulmonary pressures, in line with the findings of Rastoder et al (2025), who performed a multicentre prospective study of 250 COPD patients. They found the mean tricuspid regurgitation gradient was decreased from 35.7 ± 16.0 mmHg at the time of acute exacerbation to 29.7 ± 16.6 mmHg during the stable phase (p=0.001).[11] However, no significant differences were seen in the TAPSE or RV diameter between the two phases. This difference has significance as it indicates that the acute exacerbation may induce changes in pulmonary pressure without altering RV systolic indices measured in conventional ways. The lower TAPSE and RVFAC we observed during exacerbation in the present study, therefore, suggest a more sweeping pattern of echocardiographic abnormalities that needs to be confirmed in clinical data.

 

In 749 patients with mild COPD, Armentaro et al. (2022) explored the association between RV dysfunction and adverse cardiac events. Patients with a decreased TAPSE value were more likely to have cardiovascular events, demonstrating the clinical relevance of RV functional impairment in relatively early disease.[18] Likewise, Cook et al. (2022) found reduced TAPSE and greater right cardiac abnormalities in COPD patients with PH compared to those without PH when studying pulmonary hypertension in COPD. These are similar observations to what we saw with the lower TAPSE and higher PASP in the present study's acute exacerbation group.[19]

 

In Bangladesh, Alam and Bhuiyan (2024) measured the right heart echocardiographic parameters in 60 COPD patients. They had a mean TAPSE of 15.9 ± 3.8 mm, indicating poor RV longitudinal function, and pulmonary hypertension was also common. They found that in COPD there were functional abnormalities of the RV, and their results agree with the decrease in TAPSE in the acute exacerbation of the present study group.[20] However, their study did not include a separate stable and acute exacerbation comparison group.

 

In another study, Vesterlev et al. (2024) assessed cardiac structure and function in a prospective cohort of 796 patients with COPD compared with age- and sex-matched controls. Systolic dysfunction in the RV was defined as TAPSE < 17 mm. This study further highlighted the importance of assessing right ventricular function in COPD. It used a larger sample for its evaluation of cardiac involvement, but was not specifically designed to compare acute exacerbation with stable disease.[21]

 

Preiss et al. (2025) examined the effects of high-altitude hypoxia on RV strain impairment in 54 patients with COPD. They noted an increase in RV free-wall strain from −26.0 ± 4.9% at baseline to −23.9 ± 5.4% at high altitude (p=0.02). The percentage of patients with RV dysfunction (based on strain measurement) increased from 7.4% to 25.9%. Conventional echocardiographic parameters, however, lacked similar changes. The results indicate that RV strain is a sensitive measure of hypoxic stress and further support the link between oxygenation and RV performance.[22]

 

Bigdelu et al. (2025) studied 40 patients with stable COPD and compared echocardiographic parameters between those with and without RV dysfunction. Among the patients with RV dysfunction, RV fractional area change and RV free-wall strain were significantly decreased, while there was no significant difference in TAPSE or pulmonary artery pressure. In terms of the present study results about RVFAC, their findings are somewhat similar, but also show that sometimes one echocardiographic variable does not correlate with another. This justifies the approach to consider several parameters of the echocardiogram rather than one parameter to define RV function.[23]

 

In a systematic review of 11 observational and prospective studies, Kar et al. (2025) evaluated echocardiographic changes during acute exacerbation of COPD and in the recovery phase. Increased pulmonary artery pressure, RV dilatation, and decreased TAPSE were seen in several studies during exacerbations, and pulmonary pressures returned to normal after clinical stabilization. There was, however, wide variation between study protocols and reported outcomes. These findings are consistent with the bulk of our observations from the hypothesis, which suggested that PASP would be increased and RV functional parameters impaired during the acute exacerbation.[24]

 

Overall, the results from the present study indicate that a comprehensive echocardiographic evaluation in the patient with COPD may be useful, especially during an acute exacerbation. The usefulness of combined assessment of TAPSE, RVFAC, S′, RV dimensions, and PASP compared to only one of these. However, the findings of the study should be interpreted with caution, due to the cross-sectional study design and the fact that echocardiographic findings can be affected by differences in oxygenation, disease severity, treatment, and underlying cardiovascular status. Further follow-up studies with serial echocardiograms before and following the stabilization of an exacerbation are needed to define whether these changes are temporary or permanent.

 

Limitations

There were some limitations in this study. First, its cross-sectional design restricted its ability to assess the temporal changes in right ventricular function and did not provide a causal link between acute COPD exacerbation and right ventricular dysfunction. Secondly, the study took place in a single tertiary healthcare centre, so results may not apply to other healthcare facilities. Third, echocardiographic measurements could have been affected by variations in oxygenation status, pulmonary hemodynamics, and treatment prior to assessment. Moreover, there was no use of advanced echocardiographic parameters, such as right ventricular strain imaging, in addition to conventional parameters. The results may also have been influenced by residual confounding due to unmeasured cardiovascular and respiratory factors.

CONCLUSION

A greater prevalence of right ventricular dysfunction was observed in patients with acute exacerbation of COPD compared to those with stable COPD. Acute exacerbation patients also had reduced TAPSE, RVFAC, and tissue Doppler-derived S′ and elevated PA SP and RV dimensions. Acute exacerbation was still correlated with RV dysfunction after adjustment for selected confounding variables. These findings highlight the potential importance of echocardiographic assessment for identifying right ventricular abnormalities in patients with COPD, particularly during acute exacerbations.

REFERENCES
  1. Jo, Y.S., Long-term outcome of chronic obstructive pulmonary disease: a review. Tuberculosis and Respiratory Diseases, 2022. 85(4): p. 289.
  2. Mei, F., et al., Chronic obstructive pulmonary disease (COPD) mortality trends worldwide: An update to 2019. Respirology, 2022. 27(11): p. 941-950.
  3. Bhatt, S.P., et al., Life expectancy in chronic obstructive pulmonary disease. JAMA Internal Medicine, 2026. 186(7): p. 852-860.
  4. Cao, Z., et al., Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2021: results from the Global Burden of Disease Study 2021. BMJ Public Health, 2026. 4(1).
  5. Arrigo, M., et al., Diagnosis and treatment of right ventricular failure secondary to acutely increased right ventricular afterload (acute cor pulmonale): a clinical consensus statement of the Association for Acute CardioVascular Care of the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care, 2024. 13(3): p. 304-312.
  6. Dai, J., et al., Vascular remodeling: the multicellular mechanisms of pulmonary hypertension. International journal of molecular sciences, 2025. 26(9): p. 4265.
  7. Dini, F.L., et al., Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis. Heart Failure Reviews, 2023. 28(4): p. 757-766.
  8. Corneanu, L.E., et al., The complex relationship between heart failure and chronic obstructive pulmonary disease: a comprehensive review. Journal of clinical medicine, 2025. 14(13): p. 4774.
  9. Celli, B.R., et al., Differential diagnosis of suspected chronic obstructive pulmonary disease exacerbations in the acute care setting: best practice. American journal of respiratory and critical care medicine, 2023. 207(9): p. 1134-1144.
  10. Pereira, M.B.d.C.M., et al., Comparing cardiac function and structure and their relationship with exercise capacity between patients with stable COPD and recent acute exacerbation: a cross-sectional study. Jornal Brasileiro de Pneumologia, 2022. 48(05): p. e20220098.
  11. Rastoder, E., et al., Pulmonary pressure increases during acute exacerbation in COPD and clinical outcome. European Respiratory Journal, 2025. 66(3): p. 2500169.
  12. Keller, M., et al., Echocardiography as a tool to assess cardiac function in critical care—a review. Diagnostics, 2023. 13(5): p. 839.
  13. Vrijkorte, M.G., et al., Beyond the left ventricle: modern echocardiographic assessment of right ventricular function in tricuspid regurgitation. Cardiovascular Ultrasound, 2025. 23(1): p. 24.
  14. Dandel, M., Monitoring of the right ventricular responses to pressure overload: prognostic value and usefulness of echocardiography for clinical decision-making. Cardiovascular Diagnosis and Therapy, 2024. 14(1): p. 193.
  15. Mohammed, R.A., et al., Assessment of Cardiac Dysfunction in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Cross-Sectional Study. Cureus, 2023. 15(5): p. e39629.
  16. Kasimova, M., Prospective Echocardiographic Study for the Assessment of Right Ventricular Remodeling and Functional Impairment in COPD. International Journal of Clinical Studies and Medical Case Reports, 2025. 57.
  17. Pereira, M., et al., Comparing cardiac function and structure and their relationship with exercise capacity between patients with stable COPD and recent acute exacerbation: a cross-sectional study. J Bras Pneumol, 2022. 48(5): p. e20220098.
  18. Armentaro, G., et al., Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients. Eur J Clin Invest, 2023. 53(2): p. e13887.
  19. Cook, D.P., et al., Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease. Pulmonary circulation, 2022. 12(1): p. e12006.
  20. Alam, R. and A.R. Bhuiyan, Echocardiographic Right Heart in Patients with Chronic Obstructive Pulmonary Disease. The Insight, 2024. 7(01): p. 3-9.
  21. Vesterlev, D., et al., Cardiac structure and function in patients with chronic obstructive pulmonary disease. European Heart Journal, 2024. 45(Supplement_1): p. ehae666. 3056.
  22. Preiss, H., et al., Right ventricular strain impairment due to hypoxia in patients with COPD: a post hoc analysis of two randomised controlled trials. Open Heart, 2025. 12(1): p. e002837.
  23. Bigdelu, L., et al., Association of Carbohydrate Antigen 125 Levels and Right Ventricular Dysfunction in Patients With Chronic Obstructive Pulmonary Disease: A Cross‐Sectional Study. Health Science Reports, 2025. 8(11): p. e71410.
  24. Kar, T.A., et al., Echocardiographic Changes in Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review of Pre-and Post-treatment Findings. Cureus, 2025. 17(8): p. e89985-e89985.
Recommended Articles
Research Article
Comparison of Frailty Status in Patients Undergoing Elective Versus Emergency General Surgery
...
Published: 20/11/2026
Research Article
Prospective Validation Of The Heart Score For Risk Stratification In Acute Chest Pain: An Emergency Department Study
...
Published: 21/11/2026
Research Article
Magnetic Resonance Imaging in the Diagnostic Evaluation of Non-Traumatic Low Back Pain: A Prospective Observational Study.
...
Published: 21/11/2026
Research Article
Comparative Assessment of Fracture Resistance and Crack Propagation in Mandibular Premolars Obturated with Single-Cone and Warm Vertical Compaction Techniques Using Bioceramic Sealer
...
Published: 20/11/2026
Chat on WhatsApp
© Copyright CME Journal Geriatric Medicine